logo
Old Antibiotic Shows Promise Against Lyme Disease at Ultra-Low Doses

Old Antibiotic Shows Promise Against Lyme Disease at Ultra-Low Doses

Epoch Times09-05-2025

Scientists may be closing in on two major advances in the fight against Lyme disease: an overlooked antibiotic that eliminates the infection at exceptionally low doses and new insights into why symptoms often persist long after treatment.
In a pair of
Unlike doxycycline, piperacillin targets the Lyme disease bacteria specifically, sparing the gut microbiome from the disruption that typically accompanies doxycycline use.
'What was remarkable to us was how well piperacillin worked at really low doses,' Brandon L. Jutras, a professor in the microbiology-immunology department at Northwestern University Feinberg School of Medicine and lead researcher, told The Epoch Times. 'We don't need to provide it at a concentration that could kill other microbes.'
The team also found that remnants of the Lyme bacteria can remain in the body after being treated with antibiotics, which may
Peptidoglycan—a component of Lyme bacteria's cell wall—can linger in the body, triggering prolonged immune reactions and helping explain the symptoms of post-treatment Lyme disease (PTLD), where some patients continue to experience symptoms for months or even years after the infection is thought to be cleared.
A More Targeted Approach
Lyme disease is an infectious illness that is spread to people through the bites of infected black-legged ticks and can lead to neurological and heart complications if untreated.
Related Stories
10/22/2023
11/13/2024
Piperacillin works by interfering with the unique way Borrelia burgdorferi, the bacterium responsible for Lyme disease, builds its cell walls—a process essential for bacterial survival.
Because of this targeted mechanism, researchers believe piperacillin will spare the gut microbiome, which is often disrupted by broader-spectrum antibiotics like doxycycline. However, whether this more targeted approach could help prevent PTLD wasn't addressed in the study.
Jutras' team screened nearly 500 FDA-approved drugs, tracking how each compound affected the bacteria's ability to build its distinctive cell wall.
'We could literally watch what happened to the cell wall when we added antibiotics,' Jutras said. 'Piperacillin disrupted that process in a way that was incredibly specific to Borrelia.'
Currently, piperacillin is used to treat pneumonia and urinary tract infections and is not approved for use against Lyme disease in humans.
Beyond treatment, the researchers also see promise in piperacillin as a potential preventive measure. The idea is that one dose, received right after a tick bite, could stop the infection before it starts.
Early diagnosis is challenging since small tick bites may often go unnoticed, early symptoms may not appear for days or weeks, and not all patients develop the telltale bull's-eye rash.
Diagnostic tests often rely on antibodies that take time to form, resulting in false negatives during early infection.
'You get bit by a tick. You go to your doctor. Right now, they might tell you to wait for symptoms or a positive test result,' Jutras said. 'But with piperacillin, the idea is that you could receive a single prophylactic dose. It wouldn't harm your microbiome, and it might prevent illness altogether.'
Jutras noted that while the findings make piperacillin a promising option, it must first be tested and proven effective in human trials before physicians can prescribe it.
Some experts also caution that any antibiotic—even at low doses—can contribute to antibiotic resistance.
'The question is: does the benefit of potentially preventing Lyme disease outweigh the risk to that person's microbiome and the collective antibiotic resistance concern that we collectively face?'
'If piperacillin is proven to be highly effective, then that is a no-brainer in favor of preventing this potentially debilitating medical condition,' he said, adding that piperacillin is only available in intravenous or intramuscular form, so it's unlikely to be practical for widespread preventive use after a tick bite.
Side effects of doxycycline may include gastrointestinal discomfort, increased sensitivity to sunlight, and potential risks to bone and tooth development in children. It's also avoided during pregnancy.
Piperacillin, commonly used to treat pneumonia and urinary tract infections in combination with another antibiotic (tazobactam), carries risks of allergic reactions or changes in liver function. However, researchers note that the much lower dose used in this study—and the fact that it was not combined with a second antibiotic—may result in a safer profile.
Why Lyme Symptoms Persist
Lyme disease is now the most common vector-borne disease in the United States, with the Centers for Disease Control and Prevention estimating that approximately 500,000 Americans are diagnosed and treated
Unlike most infections, where the concern is primarily the initial acute phase, a significant worry with Lyme disease is that even after treatment, some people develop chronic symptoms of fatigue, pain, and brain fog that don't respond to further treatment.
A 2022
There is currently no single approved treatment for PTLD. Management typically focuses on relieving symptoms such as fatigue, joint pain, and brain fog through a combination of supportive care, lifestyle changes, and in some cases, extended or repeated antibiotic courses.
Jutras and his team believe that lingering bacterial debris may trigger an immune response that mimics chronic illness, even when no live bacteria remain. These peptidoglycan fragments were found in the liver and in joint fluid of patients with Lyme arthritis, where they continue to provoke an immune response.
Compared to other bacteria, Lyme bacteria's peptidoglycan is more resistant to breakdown, possibly due to its unique structure—a feature that scientists say is altered by the tick's biology.
Holistic Approaches for Prevention
To help reduce the risk of persistent symptoms, many doctors who specialize in Lyme treatment take a holistic approach to prevention and recovery.
By lowering the number of lingering pathogens and supporting immune function, these strategies can help manage and even reduce the chances of developing PTLD.
Bell highlighted the importance of identifying co-infections, such as Bartonella, Babesia, Ehrlichia, Anaplasma, or Rocky Mountain spotted fever, as well as addressing mold exposure and mycotoxins. 'If co-infections or mold toxins are present and go untreated, the patient will have a much more challenging time recovering from Lyme,' he said.
Herbal remedies such as Cryptolepsis and Japanese knotweed
Once symptoms indicating an acute infection are gone, these two botanicals may be a superior choice to antibiotics for long-term maintenance therapy after infection, Bell said.
In addition to herbal treatments, lifestyle changes—such as prioritizing quality sleep, engaging in gentle movement like walking or yoga, and minimizing exposure to environmental toxins—are a key part of recovery.
Clean tick bites with soap and water, and remove any attached ticks by using tweezers to pull them upward—without twisting or crushing them.
Early symptoms of Lyme disease, occurring 3 to 30 days after exposure, include:
Bull's-eye rash (erythema migrans)
Fever, chills, or fatigue
Muscle aches and joint pain
Swollen lymph nodes
Later symptoms, which may occur weeks to months after infection, include:
Severe joint swelling or pain
Drooping on one side of the face (facial palsy)
Numbness or tingling
Irregular heartbeat
Cognitive issues, such as memory loss

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ProZenith Launches Natural Supplement Formulated for Weight Management Support
ProZenith Launches Natural Supplement Formulated for Weight Management Support

Business Upturn

time2 hours ago

  • Business Upturn

ProZenith Launches Natural Supplement Formulated for Weight Management Support

By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

Yahoo

time3 hours ago

  • Yahoo

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company's strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will serve as strong catalysts for the stock. A clinical researcher in a lab examining a new biopharmaceutical product. The Q1 result includes ~$200K in revenue from commercial sales of RenovoCath alone. RenovoCath is an FDA-cleared and dual-balloon catheter device for the targeted isolation of blood flow and delivery of fluids. R&D expenses increased to $1.7 million, up from $1.3 million in Q1 2024, which was driven by higher employee compensation and manufacturing costs during the quarter. The company's Phase 3 TIGeR-PaC clinical trial showed promising results, with patients experiencing a median overall survival of 16 months using their targeted approach compared to 10 months with standard chemotherapy. There was also a 65% reduction in adverse events like nausea and fatigue. This trial is evaluating the company's proprietary TAMP therapy platform for the treatment of Locally Advanced Pancreatic Cancer. RenovoRx Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company that develops targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. While we acknowledge the potential of RNXT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ProZenith Launches Natural Supplement Formulated for Weight Management Support
ProZenith Launches Natural Supplement Formulated for Weight Management Support

Yahoo

time7 hours ago

  • Yahoo

ProZenith Launches Natural Supplement Formulated for Weight Management Support

U.S.-Made Product Supports General Wellness Goals with a 60-Day Refund Policy Aurora, June 06, 2025 (GLOBE NEWSWIRE) -- ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact:support@ Disclaimer:This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (925) 217-7353 CONTACT: Company: ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (925) 217-7353Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store